Table 4.

Univariate survival estimates following brain metastases

	N Patients	N Events	Median survival (months)	Lower 95% CI	Upper 95% CI	P
All	115	94	7.2	5.7	9.4
Age
< 50	65	54	8.5	6.6	11.3
≥ 50	50	40	5.5	3.5	9.4	.11
Menopausal Status
Pre	53	44	9.8	6.6	11.9
Post	62	50	5.8	3.7	8.9	.13
Race
White	82	69	8.9	5.8	10.8
Black	15	11	7.7	4.1	8.1
Other	18	14	5.5	2.8	19.8	.97
Stage
I	16	13	7.7	5.7	18.4
II	51	42	9.8	5.5	11.6
III	48	39	5.8	3.4	6.9	.61
Nuclear Grade
II	6	5	20.5	3.1	30.5
III	107	88	6.9	5.7	9.4	.32
Lymphovascular invasion
Negative	66	54	8.1	5.8	11.0
Positive	46	38	6.4	4.2	9.7	.20
Breast surgery
Breast conservation	42	32	7.7	4.6	10.8
Mastectomy	68	59	6.9	5.4	9.7	.63
Adjuvant chemotherapy
No	64	49	5.8	3.7	8.2
Yes	51	45	8.9	6.9	11.9	.57
Taxane
No	32	25	10.4	7.7	20.5
Yes	83	69	6.4	4.1	8.5	.051
Anthracycline
No	20	14	10.4	6.9	26.3
Yes	95	80	6.5	4.6	8.5	.14
Adjuvant radiation
No	38	35	6.7	3.2	11.0
Yes	77	59	7.7	5.8	9.8	.61